Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05745948Completed

COVID-19 ANtibody Responses in Cystic Fibrosis: CAR-CF

Role: collaborator

NCT05054582Completed

COVID-19 Antibody Responses In Cystic Fibrosis: CAR-CF

Role: collaborator

NCT04992234Completed

COVID-19 Antibody Responses in Cystic Fibrosis

Role: collaborator

NCT04904445Completed

COVID-19 Antibody Responses In Cystic Fibrosis

Role: collaborator

NCT06274840Recruiting

COVID-19 Antibody Responses In Cystic Fibrosis

Role: collaborator

All 5 trials loaded